EGFR and breast carcinoma: In breast cancer, luteolin suppresses the expression of cancer-promoting proteins (p-Akt, p-STAT3, and p-EGFR), reduces progestin-dependent VGF secretion and cell growth viability, and increases Bax expression [67].